GeneDx securities class action lawsuit
Analysis based on 7 articles · First reported Jul 11, 2026 · Last updated Jul 25, 2026
GeneDx Holdings Corporation's stock price dropped 49.2% following the disclosure of poor Q1 results and impairment loss. The class action lawsuit adds legal and reputational risk, potentially further depressing the stock and increasing volatility.
GeneDx Holdings Corporation Holdings Corp. faces a securities class action lawsuit filed in the United States — United States District Court for the Northern District of California, alleging failure to disclose material information during the Class Period from April 16, 2025 to May 4, 2026. On May 4, 2026, GeneDx Holdings Corporation reported Q1 2026 financial results revealing a drop in adjusted gross margin from 74% to 69%, missed revenue estimates for exome and genome lines, lowered full-year revenue guidance from $540-$550 million to $475-$490 million, and disclosed a $31.2 million impairment loss from its prior acquisition of Fabric Genomics. The stock price fell 49.2% ($33.42 per share) on the news. Lead plaintiff applications are due by August 3, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard